Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Sherman

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Annals of Surgical Oncology|February 11, 2018
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or ParagangliomaMinerva A Romero Arenas, Thereasa A Rich, Samuel M Hyde, et al.
The New England Journal of Medicine|February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancerMartin Schlumberger, Makoto Tahara, Lori J Wirth, et al.
The Journal of Clinical Endocrinology and Metabolism|January 6, 2006
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawalPamela R Schroeder, Bryan R Haugen, Furio Pacini, et al.
Oncology|May 22, 2016
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid CarcinomaAndreas M Heilmann, Vivek Subbiah, Kai Wang, et al.
ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
JCO Precision Oncology|July 9, 2025
Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
JCO Precision Oncology|February 21, 2025
<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
Ultrasound Quarterly|December 6, 2006
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates, Carol B Benson, J William Charboneau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 12, 2007
Thyroid carcinomaSteven I Sherman, Peter Angelos, Douglas W Ball, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Annals of Surgical Oncology|February 11, 2018
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or ParagangliomaMinerva A Romero Arenas, Thereasa A Rich, Samuel M Hyde, et al.
The New England Journal of Medicine|February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancerMartin Schlumberger, Makoto Tahara, Lori J Wirth, et al.
The Journal of Clinical Endocrinology and Metabolism|January 6, 2006
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawalPamela R Schroeder, Bryan R Haugen, Furio Pacini, et al.
Oncology|May 22, 2016
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid CarcinomaAndreas M Heilmann, Vivek Subbiah, Kai Wang, et al.
ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
JCO Precision Oncology|July 9, 2025
Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
JCO Precision Oncology|February 21, 2025
<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
Ultrasound Quarterly|December 6, 2006
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates, Carol B Benson, J William Charboneau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 12, 2007
Thyroid carcinomaSteven I Sherman, Peter Angelos, Douglas W Ball, et al.
Pageof 16